{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:28:30Z","timestamp":1791822510253,"version":"4.3.4"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Global Oncology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Despite an increasing number of survivors of childhood cancer (CCS) in low- and middle-income countries, survivorship care is in its nascent stages. We describe the spectrum of late effects seen, challenges faced, and lessons learnt over three decades of a late effects program in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We describe the demographics and profile of late effects of all CCS survivors enrolled in our After Completion of Treatment Clinic from February 5, 1991 (inception) to February 4, 2021. We analyzed the trends by the decade of diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>There were 3,067 CCS survivors, the median age was 18 years (range, 3-57 years), and the median follow-up was 11 years (range, 2-46 years). Two thirds (62.4%) had either no or mild late effects, 480 (15.6%), 497 (16.2%), and 162 (5.3%) had grades 2, 3, and 4 late effects, with 67 deaths reported. Notable late effects were chronic viral hepatitis (7.8%), thyroid dysfunction (7.5%), other endocrine issues (13.6%), psychosocial issues (57%), neurocognitive impairment (4.1%), and metabolic syndrome (4%). The cumulative incidence and severity of late effects showed a consistent decline by the decade of diagnosis. Twenty-two percent of survivors are lost to follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Survivors of childhood cancer treated on contemporary treatment protocols have a significantly lower side-effect profile. Attrition to long-term follow-up and psychosocial issues are significant concerns. Understanding the unique spectrum of late effects and establishing a holistic support system go a long way in ensuring the long-term physical and mental health and psychosocial concerns of childhood cancer survivors in low- and middle-income countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go.22.00044","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T16:00:24Z","timestamp":1667577624000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":32,"title":["Long-Term Outcomes in Survivors of Childhood Cancer: A 30-Year Experience From India"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-7987","authenticated-orcid":false,"given":"Maya","family":"Prasad","sequence":"first","affiliation":[{"name":"Division of Paediatric Oncology, Tata Memorial Centre, Parel, India"},{"name":"Homi Bhabha National Institute (HBNI), Anushakti Nagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-4772","authenticated-orcid":false,"given":"Savita","family":"Goswami","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI), Anushakti Nagar, India"},{"name":"Department of Psycho-oncology, Tata Memorial Centre, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-0523","authenticated-orcid":false,"given":"Girish","family":"Chinnaswamy","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI), Anushakti Nagar, India"},{"name":"Division of Pediatric Oncology, Tata Memorial Centre, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4069-023X","authenticated-orcid":false,"given":"Shripad D.","family":"Banavali","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI), Anushakti Nagar, India"},{"name":"Department of Medical Oncology, Tata Memorial Centre, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4443-2203","authenticated-orcid":false,"given":"Purna A.","family":"Kurkure","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute (HBNI), Anushakti Nagar, India"},{"name":"Pediatric Oncology and Bone Marrow Transplantation, SRCC Children's Hospital, (Narayana Health), Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-021-2210-x"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30022-X"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28556"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.6296"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1055"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31610-0"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5180"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10323"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1007\/BF02723807"},{"key":"b10","doi-asserted-by":"crossref","first-page":"e28362","DOI":"10.1002\/pbc.28362","author":"Prasad M","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27716"},{"key":"b12","volume-title":"Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 5.0 (2018)"},{"key":"b13","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"National Cancer Institute"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24679"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_196_16"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.126529"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29248"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.2589"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.2315"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-021-2213-7"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_179_16"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25781"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29704"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4058"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7900"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06788-4"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510795"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-015-0121-1"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(19)32544-8"},{"key":"b32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/ajco.12188","volume":"10","author":"Dhir AA","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"b33","first-page":"859","volume":"53","author":"Kurkure P","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2018.11.037"},{"key":"b35","first-page":"S232","volume":"63","author":"Phad P","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"b36","first-page":"iii379","volume":"22","author":"Prasad M","year":"2020","journal-title":"Neurooncology"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.025"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.10.037"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa076"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO.22.00044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T23:11:13Z","timestamp":1701299473000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO.22.00044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1200\/GO.22.00044"],"URL":"https:\/\/doi.org\/10.1200\/go.22.00044","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2022-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2200044"}}